Cytotoxicity and Mitochondrial Effects of Phenolic and Quinone-Based Mitochondria-Targeted and Untargeted Antioxidants on Human Neuronal and Hepatic Cell Lines: A Comparative Analysis
Authors:
- Carlos FernandesCFCarlos Fernandes
- Afonso J. C. VideiraAVAfonso J. C. Videira
- Caroline D. VelosoCVCaroline D. Veloso
- Sofia BenfeitoSBSofia Benfeito
- Pedro SoaresPSPedro Soares
- João D. MartinsJMJoão D. Martins
- Beatriz GonçalvesBGBeatriz Gonçalves
- José F. S. DuarteJDJosé F. S. Duarte
- António M. S. SantosASAntónio M. S. Santos
- Paulo J. OliveiraPaulo J. Oliveira
- Fernanda BorgesFernanda Borges
- José TeixeiraJTJosé Teixeira
Open Access
- 29 October 2021
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 11 (11) , 1605
Abstract
Mitochondriotropic antioxidants (MC3, MC6.2, MC4 and MC7.2) based on dietary antioxidants and analogs (caffeic, hydrocaffeic, trihydroxyphenylpropanoic and trihydroxycinnamic acids) were developed. In this study, we evaluate and compare the cytotoxicity profile of novel mitochondria-targeted molecules (generally known as MitoCINs) on human HepG2 and differentiated SH-SY5Y cells with the quinone-based mitochondria-targeted antioxidants MitoQ and SkQ1 and with two non-targeted antioxidants, resveratrol and coenzyme Q10 (CoQ10). We further evaluate their effects on mitochondrial membrane potential, cellular oxygen consumption and extracellular acidification rates. Overall, MitoCINs derivatives reduced cell viability at concentrations about six times higher than those observed with MitoQ and SkQ1. A toxicity ranking for both cell lines was produced: MC4 < MC7.2 < MC3 < MC6.2. These results suggest that C-6 carbon linker and the presence of a pyrogallol group result in lower cytotoxicity. MC3 and MC6.2 affected the mitochondrial function more significantly relative to MitoQ, SkQ1, resveratrol and CoQ10, while MC4 and MC7.2 displayed around 100–1000 times less cytotoxicity than SkQ1 and MitoQ. Based on the mitochondrial and cytotoxicity cellular data, MC4 and MC7.2 are proposed as leads that can be optimized to develop safe drug candidates with therapeutic application in mitochondrial oxidative stress-related diseases.Keywords
Funding Information
- COMPETE 2020 (CENTRO-01-0247-FEDER-038429)
This publication has 60 references indexed in Scilit:
- A Dietary Regimen of Caloric Restriction or Pharmacological Activation of SIRT1 to Delay the Onset of NeurodegenerationThe Journal of Neuroscience, 2013
- How mitochondria produce reactive oxygen speciesBiochemical Journal, 2008
- Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 1. Cationic plastoquinone derivatives: Synthesis and in vitro studiesBiochemistry (Moscow), 2008
- Targeting lipophilic cations to mitochondriaBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2008
- Mitochondrial Medicine for Aging and Neurodegenerative DiseasesNeuroMolecular Medicine, 2008
- Challenges for Research on Polyphenols from Foods in Alzheimer’s Disease: Bioavailability, Metabolism, and Cellular and Molecular MechanismsJournal of Agricultural and Food Chemistry, 2008
- Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's diseaseTrends in Molecular Medicine, 2008
- Mitochondrial Redox Cycling of Mitoquinone Leads to Superoxide Production and Cellular ApoptosisAntioxidants & Redox Signaling, 2007
- Mitochondrial targeting of quinones: Therapeutic implicationsMitochondrion, 2007
- Mitochondrial DNA Levels in Fat and Blood Cells from Patients with Lipodystrophy or Peripheral Neuropathy and the Effect of 90 Days of High-Dose Coenzyme Q Treatment: A Randomized, Double-Blind, Placebo-Controlled Pilot StudyClinical Infectious Diseases, 2004